PODD vs. TFX, GMED, BAX, NVCR, RMD, SWAV, SOLV, PEN, INSP, and MMSI
Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Teleflex (TFX), Globus Medical (GMED), Baxter International (BAX), NovoCure (NVCR), ResMed (RMD), Shockwave Medical (SWAV), NYSE:SOLV (SOLV), Penumbra (PEN), Inspire Medical Systems (INSP), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Teleflex (NYSE:TFX) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.
95.6% of Teleflex shares are held by institutional investors. 1.4% of Teleflex shares are held by insiders. Comparatively, 0.9% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Insulet received 190 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 65.98% of users gave Insulet an outperform vote while only 59.68% of users gave Teleflex an outperform vote.
Insulet has a net margin of 12.16% compared to Insulet's net margin of 11.98%. Teleflex's return on equity of 32.19% beat Insulet's return on equity.
Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
In the previous week, Teleflex had 4 more articles in the media than Insulet. MarketBeat recorded 9 mentions for Teleflex and 5 mentions for Insulet. Teleflex's average media sentiment score of 1.35 beat Insulet's score of 0.52 indicating that Insulet is being referred to more favorably in the news media.
Teleflex has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
Teleflex presently has a consensus target price of $267.50, indicating a potential upside of 28.14%. Insulet has a consensus target price of $243.21, indicating a potential upside of 41.45%. Given Teleflex's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Teleflex.
Summary
Insulet beats Teleflex on 10 of the 18 factors compared between the two stocks.
Get Insulet News Delivered to You Automatically
Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
